In Vitro Antiviral Activity and Cross-Resistance Profile of PL-100, a Novel Protease Inhibitor of Human Immunodeficiency Virus Type 1
Authors:
- 1 November 2007
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 51 (11) , 4036-4043
Abstract
Despite the success of highly active antiretroviral therapy, the current emergence and spread of drug-resistant variants of human immunodeficiency virus (HIV) stress the need for new inhibitors with distinct properties. We designed, produced, and screened a library of compounds based on an original l -lysine scaffold for their potentials as HIV type 1 (HIV-1) protease inhibitors (PI). One candidate compound, PL-100, emerged as a specific and noncytotoxic PI that exhibited potent inhibition of HIV-1 protease and viral replication in vitro ( K i , ∼36 pM, and 50% effective concentration [EC 50 ], ∼16 nM, respectively). To confirm that PL-100 possessed a favorable resistance profile, we performed a cross-resistance study using a panel of 63 viral strains from PI-experienced patients selected for the presence of primary PI mutations known to confer resistance to multiple PIs now in clinical use. The results showed that PL-100 retained excellent antiviral activity against almost all of these PI-resistant viruses and that its performance in this regard was superior to those of atazanavir, amprenavir, indinavir, lopinavir, nelfinavir, and saquinavir. In almost every case, the increase in the EC 50 for PL-100 observed with viruses containing multiple mutations in protease was far less than that obtained with the other drugs tested. These data underscore the potential for PL-100 to be used in the treatment of drug-resistant HIV disease and argue for its further development.Keywords
This publication has 34 references indexed in Scilit:
- Antiviral activity and cross-resistance profile of P-1946, a novel human immunodeficiency virus type 1 protease inhibitorAntiviral Research, 2006
- Extensive Recombination among Human Immunodeficiency Virus Type 1 Quasispecies Makes an Important Contribution to Viral Diversity in Individual PatientsJournal of Virology, 2006
- 'Working at the margins' or 'leading from behind'?: a Canadian study of hospital-community collaborationHealth & Social Care in the Community, 2005
- Treatment for Adult HIV InfectionJAMA, 2004
- Human Immunodeficiency Virus Rebound after Suppression to <400 Copies/mL during Initial Highly Active Antiretroviral Therapy Regimens, according to Prior Nucleoside Experience and Duration of SuppressionThe Journal of Infectious Diseases, 2002
- Combination Antiretroviral Therapy and Recent Declines in AIDS Incidence and MortalityThe Journal of Infectious Diseases, 1999
- In vivo emergence of HIV-1 variants resistant to multiple protease inhibitorsNature, 1995
- Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infectionNature, 1995
- Viral dynamics in human immunodeficiency virus type 1 infectionNature, 1995
- Complete nucleotide sequence of the AIDS virus, HTLV-IIINature, 1985